{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-092360","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2022-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.610665+00:00","generated_at":"2026-06-26T10:30:47.893389+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Forte Biosciences enters ATM equity sales agreement for up to $25M","bullets":["Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.","Commission of 3.0% of gross proceeds payable to Ladenburg for at-the-market sales.","Net proceeds to be used for general corporate purposes and funding of clinical programs.","Company not obligated to sell any shares; sales will be at prevailing market prices."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-092360","json":"https://secwatch.observer/filing/0001193125-22-092360.json","markdown":"https://secwatch.observer/filing/0001193125-22-092360.md","text":"https://secwatch.observer/filing/0001193125-22-092360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/0001193125-22-092360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/d345612d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T10:30:47.893389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}